GLENMARK
Glenmark Pharma
Each stock's 10,000-path forecast, rendered as light.
Glenmark Pharma (GLENMARK) Stock Analysis & Case Study
Is GLENMARK a good buy? The data-driven verdict.
Glenmark Pharma (GLENMARK) trades at ₹2,192,on the numbers it screens attractive, a Downstox Snapshot Score of 76/100.
On the numbers, Glenmark Pharma (GLENMARK) screens attractive, a Downstox Snapshot Score of 76/100, weighing fairly valued at 21.0× earnings, ROE of 30.5%, a 81% model probability of trading higher in a year. Below: the full bull case, bear case, sector-relative valuation, and a probability-weighted price target for 2027–2031.
Last updated . Data snapshot for research, not investment advice.
GLENMARK fundamentals at a glance, PE, PB, ROE, ROCE, market cap, dividend yield
Is GLENMARK overvalued? GLENMARK P/E vs its sector
GLENMARK's P/E of 21.0× sits above the sector peer median of 15.9×, so on earnings it screens richer than peers, while its 0.11% dividend yield is below the peer median of 1.65%.
GLENMARK share price target 2027, 2028, 2029, 2030, 2031, a probability view
Unlike a single guessed number, this is a probability-weighted range from a 10,000-path Monte-Carlo simulation on 2.0y of GLENMARK history (30%/yr drift, 30%/yr volatility).
| Year | Low (P10) | Median target (P50) | High (P90) | Upside vs today |
|---|---|---|---|---|
| GLENMARK 2027 | ₹1,958 | ₹2,870 | ₹4,225 | +30% |
| GLENMARK 2028 | ₹2,147 | ₹3,744 | ₹6,383 | +69% |
| GLENMARK 2029 | ₹2,513 | ₹4,836 | ₹9,329 | +118% |
| GLENMARK 2030 | ₹2,898 | ₹6,200 | ₹13,362 | +180% |
| GLENMARK 2031 | ₹3,348 | ₹8,040 | ₹18,444 | +263% |
Median (P50) is the central estimate; the P10–P90 band is the 80% confidence range. Probabilities, not promises.
What is the probability GLENMARK goes up, or doubles?
The bull case for GLENMARK
- A 21.0× P/E sits in the fair-value band, neither cheap nor stretched.
- High return on equity (30.5%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise.
- Strong ROCE (39.8%) shows the core business earns well above its cost of capital.
- A 10,000-path probability model puts a 81% chance the price is higher in a year, with a median target of ₹2,870 (+30%).
- Upside scenario: the model's optimistic (P90) 3-year path reaches ₹9,329.
The bear case & risks
- No model or past record guarantees future returns, treat this as one input, not a decision.
- Downside scenario: the model's pessimistic (P10) 3-year path falls to ₹2,513.
GLENMARK volatility & expected range, how bumpy is the ride?
Over the last 2.0 years GLENMARK compounded at 30%/year with annualized volatility of 30%. That volatility implies a 1-year 80% range of ₹1,958–₹4,225, the honest backbone behind any single price target.
GLENMARK price forecast, the full 60-month probability fan
GLENMARK price probability fan
Each band shows where 10,000 simulated paths land. The wider the fan, the more uncertainty.
Probability of key outcomes
What are the odds GLENMARK hits common targets within the simulated horizon?
Full multi-horizon detail on the GLENMARK price target & forecast page.
GLENMARK Piotroski F-Score: 4/9, how financially strong is it?
The Piotroski F-Score grades financial strength on nine profitability, leverage and efficiency checks. GLENMARK scores 4/9,mixed financial health.
GLENMARK MTF margin & leverage, Upstox, Zerodha, Groww, Dhan
Margin Trading Facility lets you buy GLENMARK with part of the capital. Lower margin % = higher leverage. Rates compared across brokers (no competitor publishes this):
| Broker | Margin required | Approx. leverage |
|---|---|---|
| Upstox | 29.7% | 3.4× |
| Zerodha | 25.3% | 4.0× |
| DhanCHEAPEST | 23.0% | 4.3× |
Compare every broker on the GLENMARK MTF page.
GLENMARK vs peers,sector comparison
About Glenmark Pharma: sector, index & market-cap context
Glenmark Pharma (GLENMARK) is a mid-cap NSE-listed company, and a constituent of the Nifty 100 index group, with a market capitalisation of ₹61,843 Cr. See more Nifty 100 stocks.
How the GLENMARK Snapshot Score & forecast are built
The Downstox Snapshot Score is a transparent, rules-based read of Glenmark Pharma's public fundamentals plus a statistical forecast, not an analyst opinion. It rewards low-to-fair valuation, high ROE/ROCE, a strong Piotroski F-Score, a dividend, low volatility and a favourable probability of upside; it penalises rich valuations, weak capital efficiency, a low F-Score and high volatility. The price target is a 10,000-path Monte-Carlo simulation on real historical volatility, a distribution, not a single guess. The bull and bear cases are generated from the same data, so you always see both sides.
This is information, not investment advice. Do your own due diligence and consult a SEBI-registered adviser before investing.
GLENMARK analysis, FAQs
Is Glenmark Pharma (GLENMARK) a good buy?
On the numbers, Glenmark Pharma (GLENMARK) screens attractive, a Downstox Snapshot Score of 76/100, weighing fairly valued at 21.0× earnings, ROE of 30.5%, a 81% model probability of trading higher in a year. This is a data snapshot for research, not investment advice.
Is GLENMARK overvalued or undervalued?
GLENMARK trades at 21.0× earnings versus a peer median of 15.9×, so it screens richer than its sector peers.
What is the GLENMARK share price target for 2031?
GLENMARK's probability-weighted 2031 median target is ₹8,040, with an 80% range of ₹3,348–₹18,444 (10,000-path Monte-Carlo).
What is the probability GLENMARK doubles in 5 years?
The modelled probability of GLENMARK reaching ₹4,427 (2×) within 5 years is 81%.
What is the bull case for GLENMARK?
A 21.0× P/E sits in the fair-value band, neither cheap nor stretched. High return on equity (30.5%), the business compounds shareholder capital efficiently, the hallmark of a quality franchise. Strong ROCE (39.8%) shows the core business earns well above its cost of capital.
What are the risks in GLENMARK?
No model or past record guarantees future returns, treat this as one input, not a decision.